Pertuzumab1yearTamoxifenOlaparib10yearsRadiationtherapyPercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)TNBC2yearsLoperamideprophylaxisVenlafaxineTC (docetaxel /cyclophosphamide)ExemestanePembrolizumabEverymonthAromataseinhibitorsAnthracyclinesTaxanesTDM-1(Ado-trastuzumabemtansine)Intermediate(11-25)CapecitabineAbemaciclibChemoendocrinetherapyLVEFmonitoringPertuzumab1yearTamoxifenOlaparib10yearsRadiationtherapyPercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)TNBC2yearsLoperamideprophylaxisVenlafaxineTC (docetaxel /cyclophosphamide)ExemestanePembrolizumabEverymonthAromataseinhibitorsAnthracyclinesTaxanesTDM-1(Ado-trastuzumabemtansine)Intermediate(11-25)CapecitabineAbemaciclibChemoendocrinetherapyLVEFmonitoring

Early-Stage Breast Cancer - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Pertuzumab
  2. 1 year
  3. Tamoxifen
  4. Olaparib
  5. 10 years
  6. Radiation therapy
  7. Percentage needed to be considered HR+ (adjuvant endocrine therapy considered)
  8. TNBC
  9. 2 years
  10. Loperamide prophylaxis
  11. Venlafaxine
  12. TC (docetaxel / cyclophosphamide)
  13. Exemestane
  14. Pembrolizumab
  15. Every month
  16. Aromatase inhibitors
  17. Anthracyclines
  18. Taxanes
  19. TDM-1 (Ado-trastuzumab emtansine)
  20. Intermediate (11-25)
  21. Capecitabine
  22. Abemaciclib
  23. Chemoendocrine therapy
  24. LVEF monitoring